IL103459A0 - Decahydroisoquinoline derivatives and pharmaceutical compositions containing them - Google Patents
Decahydroisoquinoline derivatives and pharmaceutical compositions containing themInfo
- Publication number
- IL103459A0 IL103459A0 IL103459A IL10345992A IL103459A0 IL 103459 A0 IL103459 A0 IL 103459A0 IL 103459 A IL103459 A IL 103459A IL 10345992 A IL10345992 A IL 10345992A IL 103459 A0 IL103459 A0 IL 103459A0
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- hiv
- compounds
- treatment
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical class C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 title 1
- 208000030507 AIDS Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108010010369 HIV Protease Proteins 0.000 abstract 1
- 102000015636 Oligopeptides Human genes 0.000 abstract 1
- 108010038807 Oligopeptides Proteins 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 229940042443 other antivirals in atc Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78147091A | 1991-10-23 | 1991-10-23 | |
| US92999192A | 1992-08-21 | 1992-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL103459A0 true IL103459A0 (en) | 1993-03-15 |
Family
ID=27119862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL103459A IL103459A0 (en) | 1991-10-23 | 1992-10-16 | Decahydroisoquinoline derivatives and pharmaceutical compositions containing them |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5502060A (de) |
| EP (1) | EP0539192B1 (de) |
| JP (1) | JPH0678314B2 (de) |
| AT (1) | ATE175412T1 (de) |
| AU (1) | AU649170B2 (de) |
| CA (1) | CA2081134A1 (de) |
| DE (1) | DE69228106T2 (de) |
| ES (1) | ES2125251T3 (de) |
| IL (1) | IL103459A0 (de) |
| NZ (1) | NZ244773A (de) |
| WO (1) | WO1993008184A1 (de) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6313094B1 (en) | 1990-12-11 | 2001-11-06 | Japan Energy Corporation | β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors |
| US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| DE69333270T2 (de) | 1992-03-11 | 2004-08-05 | Narhex Ltd. | Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen |
| US5888992A (en) | 1992-03-11 | 1999-03-30 | Narhex Limited | Polar substituted hydrocarbons |
| BR9306058A (pt) * | 1992-03-11 | 1997-11-18 | Narhex Ltd | Derivados de amina de hidrocarbonetos oxo- e hidroxi- substituidos |
| US6071895A (en) | 1992-03-11 | 2000-06-06 | Narhex Limited | Polar-substituted hydrocarbons |
| US7141609B2 (en) | 1992-08-25 | 2006-11-28 | G.D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
| DE122007000045I2 (de) | 1992-08-25 | 2011-07-21 | Gd Searle Llc Gd Searle Llc | Darunavir oder pharmazeutisch vertragliche Salze, Hydroxyethylaminosulfonamide verwendbar als InhibiEster oder Prodrugs davon. toren retroviraler Proteasen. |
| US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| US5846993A (en) * | 1992-12-22 | 1998-12-08 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| WO1994026749A1 (en) * | 1993-05-14 | 1994-11-24 | Merck & Co., Inc. | Hiv protease inhibitors |
| ES2174921T3 (es) * | 1993-12-15 | 2002-11-16 | Merck & Co Inc | Inhibidores de la proteasa del vih. |
| US5733882A (en) * | 1994-01-17 | 1998-03-31 | Smithkline Beecham Corporation | Retroviral protease inhibitors |
| US5480887A (en) * | 1994-02-02 | 1996-01-02 | Eli Lilly And Company | Protease inhibitors |
| DE69426655T2 (de) * | 1994-02-02 | 2001-06-13 | Eli Lilly And Co., Indianapolis | Hiv-protease inhibitoren und zwischenprodukte |
| US5527829A (en) * | 1994-05-23 | 1996-06-18 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| US6222043B1 (en) | 1995-06-30 | 2001-04-24 | Japan Energy Corporation | Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof |
| US5932550A (en) * | 1995-06-30 | 1999-08-03 | Japan Energy Corporation | Dipeptide compound or pharmaceutically acceptable salt thereof and medical use thereof |
| DE19531685A1 (de) * | 1995-08-29 | 1997-03-06 | Bayer Ag | Neue heterocyclisch substituierte Pseudopeptide |
| US5705647A (en) * | 1996-09-05 | 1998-01-06 | Agouron Pharmaceuticals, Inc. | Intermediates for making HIV-protease inhibitors |
| US5925759A (en) | 1996-09-05 | 1999-07-20 | Agouron Pharmaceuticals, Inc. | Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors |
| US5962725A (en) | 1996-09-05 | 1999-10-05 | Agouron Pharmaceuticals, Inc. | Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir |
| EP0900566A4 (de) | 1996-12-27 | 2001-04-25 | Japan Energy Corp | Neuartige tripeptidvebindungen und arzneimittel gegen aids |
| US6001851A (en) * | 1997-03-13 | 1999-12-14 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| US6084107A (en) * | 1997-09-05 | 2000-07-04 | Agouron Pharmaceuticals, Inc. | Intermediates for making HIV-protease inhibitors |
| WO1999029311A1 (en) * | 1997-12-08 | 1999-06-17 | The Scripps Research Institute | Hiv/fiv protease inhibitors having a small p3 residue |
| US6803466B1 (en) * | 1997-12-08 | 2004-10-12 | The Scripps Research Institute | HIV/FIV protease inhibitors having a small P3 residue |
| AU4828199A (en) * | 1998-06-23 | 2000-01-10 | Board Of Trustees Of The University Of Illinois, The | Multi-drug resistant retroviral protease inhibitors and associated methods |
| PT2336134T (pt) | 1998-06-23 | 2016-10-19 | The Board Of Trustees Of The Univ Of Illionis | Ensaio de aptidão e métodos para reduzir a resistência do hiv à terapia |
| US6613764B1 (en) | 1999-01-06 | 2003-09-02 | The United States Of America As Represented By The Department Of Health And Human Services | Aspartic protease inhibitors |
| EP1194449B1 (de) * | 1999-06-28 | 2010-09-22 | Oklahoma Medical Research Foundation | Inhibitoren des memapsin 2 und ihre verwendung |
| EP1278541A1 (de) * | 2000-04-28 | 2003-01-29 | The Government of The United States of America, as represented by The Department of Health and Human Services | Verbesserung der immunogenität bei der verwendung einer kombination von dns und vacciniavirus-vektor impfstoffen |
| US7109230B2 (en) * | 2002-01-07 | 2006-09-19 | Sequoia Pharmaceuticals, Inc. | Resistance-repellent retroviral protease inhibitors |
| US7157489B2 (en) * | 2002-03-12 | 2007-01-02 | The Board Of Trustees Of The University Of Illinois | HIV protease inhibitors |
| AU2003301841A1 (en) * | 2002-05-01 | 2004-06-07 | National Institutes Of Health | Immunotherapy regimens in hiv-infected patients |
| EP1589018A4 (de) | 2002-12-27 | 2007-03-14 | Sumitomo Chemical Co | Herstellungsverfahren für hexahydrofurofuranol-derivate, zwischenprodukt davon und herstellungsverfahren dafür |
| WO2005087728A1 (en) * | 2004-03-11 | 2005-09-22 | Sequoia Pharmaceuticals, Inc. | Resistance-repellent retroviral protease inhibitors |
| JP2005314374A (ja) * | 2004-03-31 | 2005-11-10 | Daiso Co Ltd | ３−ヒドロキシチオランの新規製法 |
| AU2005244121B2 (en) | 2004-05-07 | 2012-01-19 | Sequoia Pharmaceuticals, Inc. | Resistance-repellent retroviral protease inhibitors |
| WO2007021886A2 (en) * | 2005-08-10 | 2007-02-22 | Oklahoma Medical Research Foundation | Truncated memapsin 2 for use for treating alzheimer's disease |
| GB2443591B (en) * | 2005-09-07 | 2010-04-28 | Secr Defence | Adjuvanted vaccine |
| GB0519871D0 (en) * | 2005-09-30 | 2005-11-09 | Secr Defence | Immunogenic agents |
| US8323664B2 (en) | 2006-07-25 | 2012-12-04 | The Secretary Of State For Defence | Live vaccine strains of Francisella |
| GB0900455D0 (en) | 2009-01-13 | 2009-02-11 | Secr Defence | Vaccine |
| GB0901411D0 (en) | 2009-01-29 | 2009-03-11 | Secr Defence | Treatment |
| GB0901423D0 (en) | 2009-01-29 | 2009-03-11 | Secr Defence | Treatment |
| GB0906234D0 (en) | 2009-04-14 | 2009-05-20 | Secr Defence | Vaccine |
| WO2011106705A2 (en) | 2010-02-26 | 2011-09-01 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Dna-protein vaccination protocols |
| KR101680302B1 (ko) * | 2010-07-13 | 2016-11-29 | 김찬숙 | 세포의 다핵분열을 유도할 수 있는 조성물 |
| US8841467B2 (en) | 2010-11-23 | 2014-09-23 | Mylan Laboratories Limited | Process for the preparation of (3R, 3aS, 6aR)-hexahydrofuro [2, 3-b] furan-3-ol |
| EP2883858B1 (de) | 2012-08-09 | 2017-12-27 | Sumitomo Chemical Company Limited | Verfahren zur herstellung eines hexahydrofurofuranolderivats |
| ES2959642T3 (es) | 2015-05-13 | 2024-02-27 | The Us Secretary Of The Department Of Health And Human Services | Metodos y composiciones para inducir una respuesta inmunitaria mediante construcciones con elementos conservados |
| US20250360199A1 (en) | 2022-07-07 | 2025-11-27 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Immunogens and methods for inducing an immune response |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340588C (en) * | 1988-06-13 | 1999-06-08 | Balraj Krishan Handa | Amino acid derivatives |
| CA2012306A1 (en) * | 1989-03-28 | 1990-09-28 | Werner Neidhart | Amino acid derivatives |
| GB8927915D0 (en) * | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Novel alcohols |
| GB8927913D0 (en) * | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
| CA2032259A1 (en) * | 1989-12-18 | 1991-06-19 | Wayne J. Thompson | Hiv protease inhibitors useful for the treatment of aids |
-
1992
- 1992-10-14 WO PCT/US1992/008758 patent/WO1993008184A1/en not_active Ceased
- 1992-10-16 IL IL103459A patent/IL103459A0/xx unknown
- 1992-10-16 NZ NZ244773A patent/NZ244773A/en unknown
- 1992-10-21 ES ES92309639T patent/ES2125251T3/es not_active Expired - Lifetime
- 1992-10-21 DE DE69228106T patent/DE69228106T2/de not_active Expired - Fee Related
- 1992-10-21 EP EP92309639A patent/EP0539192B1/de not_active Expired - Lifetime
- 1992-10-21 AT AT92309639T patent/ATE175412T1/de not_active IP Right Cessation
- 1992-10-22 AU AU27253/92A patent/AU649170B2/en not_active Ceased
- 1992-10-22 CA CA002081134A patent/CA2081134A1/en not_active Abandoned
- 1992-10-23 JP JP4309474A patent/JPH0678314B2/ja not_active Expired - Lifetime
-
1994
- 1994-10-25 US US08/328,936 patent/US5502060A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0539192B1 (de) | 1999-01-07 |
| AU2725392A (en) | 1993-04-29 |
| DE69228106D1 (de) | 1999-02-18 |
| ATE175412T1 (de) | 1999-01-15 |
| CA2081134A1 (en) | 1993-04-24 |
| DE69228106T2 (de) | 1999-07-15 |
| EP0539192A1 (de) | 1993-04-28 |
| NZ244773A (en) | 1994-10-26 |
| US5502060A (en) | 1996-03-26 |
| JPH05239031A (ja) | 1993-09-17 |
| AU649170B2 (en) | 1994-05-12 |
| JPH0678314B2 (ja) | 1994-10-05 |
| ES2125251T3 (es) | 1999-03-01 |
| WO1993008184A1 (en) | 1993-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2725392A (en) | Hiv protease inhibitors | |
| CA2195027A1 (en) | HIV Protease Inhibitors Useful for the Treatment of AIDS | |
| PL310895A1 (en) | Hiv protease inhibitors in aids treating pharmaceutic compositions | |
| MY109834A (en) | Benzoxazinones as inhibitors of hiv reverse transcriptase | |
| DE69531944D1 (de) | Neue hiv-protease-inhibitoren | |
| AU6787690A (en) | Amino acid derivatives | |
| HU9601649D0 (en) | Hiv protease inhibitors | |
| WO1996000068A3 (en) | Combination therapy for hiv infection | |
| PL318506A1 (en) | Combination of hiv protease inhibitors | |
| FI970565A0 (fi) | HIV-proteaasia inhiboiva yhdistelmä |